8.20AM - 18.30PM EDT | Boston, MA

8:20 am Chair’s Opening Remarks

Cannabinoids and COVID-19

8:30 am Advances in Cannabis research: Future Therapeutics and Ajunctive Treatment for COVID-19


  • Biology effects of cannabis is mediated by action on human endocannabinoid system
  • Explosion of new knowledge that the effects of cannabis are encoded in our genome on chromosomes 1 and Cannabinoid receptors and endocannabinoids are involved in reproduction and implantation of fertilized egg in the uterus
  • Cannabinoid receptors are therapeutic targets for the treatment of mental and neurological disorders

9:00 am Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response

  • Marsha R. Rosner Professor, Ben May Dept. for Cancer Research Gordon Center for Integrative Sciences, University of Chicago


  • CBD and its metabolites but not congeneric cannabinoids, potently block SARS-CoV-2 replication in lung epithelial cells
  • CBD acts after cellular infection, inhibiting viral gene expression and upregulating the interferon antiviral signaling pathway
  • A cohort of human patients previously taking CBD had significantly lower SARS-CoV-2 infection incidence of up to an order of magnitude relative to matched pairs or the general population

Educating Physicians and Patients to Ensure Clinical Utility

9:30 am Educating Patients and Clinicians to Understand and Appreciate the Clinical Value of Cannabinoids


  • Highlight the current understanding doctors have of cannabinoid medications and their attitudes towards them
  • Discuss how both cannabinoid medications and medical cannabis can coexist by discussing their various applications
  • Discuss the work of ACHEM and how cannabinoid pharmaceuticals can get involved

10:00 am Roundtable Discussion: Equipping Physicians with the Knowledge and Language to Best Represent Cannabinoid Pharmaceuticals and their Potential Benefits


  • At your tables we will discuss what you believe are essential things to consider when communicating with clinicians and patients, you will:
  • Describe and explain what a cannabinoid medicine is
  • Describe the differences between a synthetic and plant based cannabinoid therapeutic
  • Explain the potential risks of a medication

10:30 am Morning Coffee Break

Carousel: The Future Companies Disrupting Cannabinoid Pharmaceutical Development


This part of the conference will feature new companies in field giving short pitches on the technology they have developed and how they intend to disrupt the cannabinoid space

11:00 am Introduction to the Carousel

11:05 am Cannabis Phytotherapy


  • Phytocomplex and isolate approach
  • Standardization of botanical extracts
  • Patient’s need: what do they actually want and how can it be delivered

11:20 am Optimising Drug Delivery for Cannabinoids


  • Discuss the key drug delivery challenges Zylo aimed to overcome
  • Discuss how Zylo is optimising drug delivery of Cannabinoids

11:35 am Nanotechnology Based Cannabinoid Drug Formulations


  • Technology Overview: opportunities in nanotechnology and the microfluidic approach
  • Characterization Methods & Sample Preparation Challenges: polymer nanoparticles, liposomes, emulsions on the HPLC
  • Research Findings: the impact of lipid composition on liposome stability and cannabinoid drug encapsulation efficiency

11:50 am Panel: The Key Lessons Learned as a New Company Breaking into the Cannabinoid Pharmaceutical Field

12:20 pm Lunch Break

Investment, Funding and Forming Valuable Partnerships to Drive Cannabinoid Pharmaceuticals Forward

1:30 pm Panel Discussion: Reviewing the Status of the Markets and Investment Trends


  • Look back at the last 12 months of investment and identify key learnings we can take from the year
  • Discuss what investors have taken away from the GW pharmaceuticals/Greenwich Biosciences acquisition and what it could mean for the entire field

Protecting Your Work with Strong Intellectual Property Strategy

2:00 pm Strategies for Building a Robust Patent Portfolio


  • Leveraging the Power of Unexpected Results- how to distinguish from existing art
  • The Power of Method Claims- how to combine method claims with regulatory approval, or with 271(g) enforcement strategies
  • Multi-jurisdiction patent strategies

2:30 pm Fireside Chat: Meet the Cannabinoid IP Specialists


  • Hear perspectives on IP strategy and enforcement from key opinion leaders at the heart of the cannabis and cannabinoid field
  • Understand the IP lifecycle, and how work at one stage can influence another. For example what types of things your team can do during prosecution to prepare a company for litigation.

3:00 pm Cannabinoid Receptor 2 Agonists on Their Way To Clinics – Snapshots Of A Drug Discovery Program

  • Uwe Grether Senior Principle Scientist, F. Hoffmann-La Roche Ltd.


  • Drug discovery
  • Academia industry collaborations
  • Biomarkers and chemical probes

3:30 pm Afternoon Break

Preclinical and Early Clinical Development

4:00 pm Optimization and Efficacy of a Cannabinoids Based Formulation in a Preclinical Model of Osteoarthritis


  • Enhanced deep tissue delivery formulation development results
  • Evaluation of various cannabinoid combinations and ratios in osteoarthritis
  • Safety and efficacy of RHO Phyto Deep tissue gels in animal model of osteoarthritis versus placebo and current available OTC pain gels

4:30 pm Carrying Out Translational Studies in Cannabinoid Medicine

  • Hunter Land Senior Scientific Director, Canopy Growth Corp


  • Discuss the critical decisions that must be made to ensure clinical studies yield meaningful results
  • Identify useful biomarers for your specific condition

5:00 pm CBD as a Pharmaceutical: Requirements and Phase 1 Clinical Trial Results

  • Mark Rosenfeld Chief Executive Officer & Chief Science Officer, Ananda Scientific


  • Increasing the oral bioavailability of CBD, in a manner acceptable to regulatory authorities in the United States and elsewhere, is essential to making it a reliable medicine
  • A Phase 1 PK shows confirms that ANANDA Scientific’s uniquely enhanced CBD, or Liquid StructureTM CBD, rapidly and prodigiously enters the body, with Tmax at 1 hour instead of the 2-3 hours seen with regular CBD
  • Liquid Structure CBD may have a desirably heightened pharmacodynamic impact than does regular CBD, especially evidenced by sizable reductions in TNF-α, an inflammation protein associated with many autoimmune diseases as well as the deadly cytokine storms that outfall COVID-19 and influenza infection

Building Reliable Supply Chains Around the World and Preparing for Commercialization

5:30 pm The Value of a Building a Reliable, Flexible and Cost Competitive Manufacturing Platform


  • Manufacturing technology to implement and the value drivers for a process
  • Target market(s) and considerations
  • Selecting the right partners / CDMO’s for a successful development, scale up and commercialization path

6:00 pm The Art and Science of Commercializing Cannabinoids to Europeans


  • Reverse-engineering the patient need (or consumer interest)
  • Distinguishing between medical and wellness applications and channels
  • Building infrastructure – from contract manufacturers to market research and go-to-market plans

6:30 pm End of Conference Day Two